RMi Pre-opening: more econs

February 27, 2026 7:54am

Updated:January’s producer price index, which is a measure of wholesale inflation, came in hotter than expected at a 0.5% increase for the month versus economists predict of 0.3%. Excluding food and energy prices, core PPI recorded a 0.8% gain; undermining share pricing as earnings LPS (loss-per-share) delve on, assist in lowering the bar

Futures are falling with the Nasdaq staring at its steepest monthly drop since March 2025; it’s still about holding and watching what from which to the bank or the toilet

Pre-open Signals: 3 Positive and 3 Negative Indications; if you understand probabilities, the inevitable is easier to maneuver

Remember that overnight action in futures don't necessarily translate into actual trading in today’s regular stock market session.

Never leave retail investor uninformed … I say what others won’t, so you can KNOW what others can’t!

“I hate to be considered negative or contrarian but, this is a NO spin zone and truth is its product; I can always be WRONG but, I am mostly EARLY!”

Thursday’s RMi Closing Bell: Luck was a happening … https://www.regmedinvestors.com/articles/14330

I chose to speak-up when many analysts, brokers and commentators have shut-up!

Friday's Update :The pre-open Dow futures are DOWN -1.15% or (-572 points), the S&P futures are DOWN -0.88% or (-63 points) and the Nasdaq futures are DOWN -0.98% or (-246 points)

• U.S. stock futures are are diving after PPI release Friday, 2/27
• European markets opened mixed and rolling up,
• Asia Pacific markets also traded mixed

Economic Data: PPI (Producer Price Index) and its cores (year over years), Construction Spending (Nov & Dec) and Chicago Business Barometer (PMI)

Henry’omics: We need to more than consider the market’s setting to grasp the micro re “our” universe of cell and gene therapy companies

• Thursday: The Dow closed UP +17.05 points or +0.03%, the S&P closed DOWN -37.27 points or -0.54% while the Nasdaq closed DOWN -273.694 points or -1.18%
• Wednesday: The Dow closed UP +307.65 points or +0.63%, the S&P closed UP +56.06 points or +0.81% while the Nasdaq closed UP +288.396 points or +1.26%
• Tuesday: The Dow closed UP +370.44 points or +0.76%, the S&P closed UP +52.32 points or +0.77% while the Nasdaq closed UP +236.409 points or +1.05%
• Monday: The Dow closed DOWN -821.91 points or -1.66%, the S&P closed DOWN -71.76 points or -1.04% while the Nasdaq closed DOWN -258.796 points or -1.13%

• Last week: The S&P 500 was up +1.1%, the Dow +0.3% and the Nasdaq was up +1.5%.
• The previous week: The S&P 500 was down -1.4%, the Dow -1.2% and the Nasdaq was down -2.1%.
• January: The S&P 500, Dow were up more than 1% and the Nasdaq had a 0.7% gain.

Q1/26 – Q1 February – 1 market holiday, 11 positive and 7 negative closes

• January – 2 holiday, 2 neutral, 9 negative and 9 positive closes 

Q4:

• December, 1 holiday, 8 positive and 12 negative closes
• November, 1 holiday, 8 positive and 11 negative sessions
• October, 1 neutral, 10 positive and 12 negative closes

Companies in my headlights – It’s your decision; I provide ideas and context

I post about “indication intelligence” looking toward investment conferences … to assist investors with insight into sector vulnerabilities and strengths.  A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

• Multiple earnings coming as sector releases Qs and FY25 …

Wave Life Sciences (WVE) closed up +$0.82 after Wednesday’s +$0.52 with a negative -$0.17 or -1.11% pre-open

Beam Therapeutics (BEAM) closed down -$0.69 after Wednesday’s -$2.68 after Tuesday’s +$3.96 after Monday’s +$0.74 with a negative -$0.31 or -1.07% pre-open

Sarepta Therapeutics (SUPN) closed down -$1.52 with a negative -$0.20 or -1.15% pre-open

Entrada Therapeutics (TRDA) closed up +$0.81 after Wednesday’s +$0.50 with a positive +$0.19 or +1.49% pre-open

Capricor Therapeutics (CAPR) closed down -$0.46 after Wednesday’s +$0.44 with a positive +$0.51 or +1.83% pre-open

BioNTech (BNTX) closed down -$1.04 after Wednesday’s -$1.05 after Tuesday’s +$0.96 after last Monday’s -$0.21 with a positive +$1.12 or +1.03% pre-open

The BOTTOM LINE: Welcome to my world of defining the “grey’ in our universe!

Sensitivity ... STILL ...tempers optimism … futures are wavering, although I see some green in the sector – I’m holding!

• Dow futures were steady versus fair value. S&P 500 futures were just above break-even and Nasdaq 100 futures edged lower.

A market bell weather, Nvidia (NVDA) earnings and revenue beat fiscal Q4 views, as it reported another Q of accelerating growth for both. The AI chipmaker also guided higher on the current Q1.

• The NVDA “earnings report is important for AI infrastructure firms broadly, from fiber-optic plays to heavy construction firms to energy producers. Many have rallied in recent days.” <IBD>

Are the dice … hot, as they say it is a “crap shoot”        

• Keep that in mind   the latest batch of buying opportunities. If you take advantage, you have to be nimble, cutting losers quickly and not letting small winners turn into losers. 

Investors will look for further insight into sector earnings; the Q4 and FY25 earnings reporting cycle. So far …

• Tuesday - 2/24 – AxoGen (AXGN), Beam Therapeutics (BEAM) and Supernus Therapeutics (SUPN)
• Wednesday – 2/25 – MiMedx (MDXG), Ionis Pharmaceuticals (IONS) and Sarepta Therapeutics (SRPT)
• Thursday – 2/26 – Intellia Therapeutics (NTLA), Wave Life Sciences (WVE), Mesoblast (MESO), Vericel (VCEL) and BioLife Solutions (BLFS)
• Monday – 3/2 uniQure NV (QURE)
• Thursday - 3/5 Regenxbio (RNX)
• Tuesday – 3/10 – BioNTech, SE (BNTX)

Welcome to my world of defining the “grey’ in our universe!

• I hate to be so negative or contrarian but, this is a NO spin zone and facts and truth are its products; I can always be WRONG but, I am mostly EARLY!
• if I wanted to be liked, I wouldn’t have been an analyst/journalist.

February – 4^th week

• 2/26 – Thursday closed positive with 24incliners, 14 decliners and 2 flats
• 2/25 – Wednesday closed positive with 20 incliners, 19 decliners and 1 flat
• 2/24 - Tuesday closed positive with 32 incliners, 5 decliners and 3 flats
• 2/23 - Monday closed positive with 24 incliners, 13 decliners and 3 flats

February – 3^rd week

• 2/20 - Friday closed negative with 13 incliners, 26 decliners and 1 flat
• 2/19 – Thursday closed positive with 25 incliners, 12 decliners and 3 flats
• 2/18 - Wednesday closed positive with 30 incliners, 8 decliners and 2 flats
• 2/17 – Tuesday closed positive with 27 incliners, 11 decliners and 2 flats
• 2/16 – Monday was market holiday

As the leading voice of cell and gene therapy investors; I am NOT always a doom analyst/journalist but a man who has been “there” (BUY, SELL, VC and multiple operating roles) with the gray hair and a readership following with real numbers to prove it!

• I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC):

The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed.